Delisting riskPopularity #4,237
AKTX · NASDAQ · Biotechnology

Akari Therapeutics (ADR) (AKTX)

Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.

$9.45
vs last close−0.60 (−5.97%)